The Journal of Allergy and Clinical Immunology
Volume 124, Issue 2 , Pages 292-300.e97 , August 2009

Clinical efficacy and immune regulation with peanut oral immunotherapy

  • Stacie M. Jones, MD

      Affiliations

    • Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark
    • ,
  • Laurent Pons, PhD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Joseph L. Roberts, MD, PhD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Amy M. Scurlock, MD

      Affiliations

    • Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark
    • ,
  • Tamara T. Perry, MD

      Affiliations

    • Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark
    • ,
  • Mike Kulis, PhD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Wayne G. Shreffler, MD, PhD

      Affiliations

    • Department of Pediatrics, Mount Sinai Medical Center, New York, NY
    • ,
  • Pamela Steele, CPNP

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Karen A. Henry, RN

      Affiliations

    • Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark
    • ,
  • Margaret Adair, MD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • James M. Francis, PhD

      Affiliations

    • Imperial College, London, United Kingdom
    • ,
  • Stephen Durham, MD

      Affiliations

    • Imperial College, London, United Kingdom
    • ,
  • Brian P. Vickery, MD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Xiaoping Zhong, MD, PhD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • A. Wesley Burks, MD

      Affiliations

    • Department of Pediatrics, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: A. Wesley Burks, MD, Duke University Medical Center, Box 2644, Durham, NC 27710.

Received 19 November 2008 ,Revised 28 April 2009 ,Accepted 12 May 2009.

References 

  1. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol. 2003;112:1203–1207
  2. Emmett SE, Angus FJ, Fry JS, Lee PN. Perceived prevalence of peanut allergy in Great Britain and its association with other atopic conditions and with peanut allergy in other household members. Allergy. 1999;54:380–385
  3. Kanny G, Moneret-Vautrin DA, Flabbee J, Beaudouin E, Morisset M, Thevenin F. Population study of food allergy in France. J Allergy Clin Immunol. 2001;108:133–140
  4. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191–193
  5. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119:1016–1018
  6. Sampson HA. Update on food allergy. J Allergy Clin Immunol. 2004;113:805–819
  7. Joshi P, Mofidi S, Sicherer SH. Interpretation of commercial food ingredient labels by parents of food-allergic children. J Allergy Clin Immunol. 2002;109:1019–1021
  8. Vierk K, Falci K, Wolyniak C, Klontz KC. Recalls of foods containing undeclared allergens reported to the US Food and Drug Administration, fiscal year 1999. J Allergy Clin Immunol. 2002;109:1022–1026
  9. Altschul AS, Scherrer DL, Munoz-Furlong A, Sicherer SH. Manufacturing and labeling issues for commercial products: relevance to food allergy. J Allergy Clin Immunol. 2001;108:468
  10. Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics. 1998;102:e6
  11. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–1034
  12. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–262
  13. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–751
  14. Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther. 2003;17:459–465
  15. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004;59:980–987
  16. Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119:199–205
  17. United States Department of Agriculture. USDA National Nutrient Database for Standard Reference, release 21 (2002). Available at: http://ars.usda.gov/Services/docs.htm?docid=17477. Accessed January 20, 2009.
  18. McDermott RA, Porterfield HS, El Mezayen R, Burks AW, Pons L, Schlichting DG, et al. Contribution of Ara h 2 to peanut-specific, immunoglobulin E-mediated, cell activation. Clin Exp Allergy. 2007;37:752–763
  19. Wanich N, Nowak-Wegrzyn A, Sampson HA, Shreffler WG. Allergen-specific basophil activation associated with clinical tolerance in patients with milk allergy. J Allergy Clin Immunol. 2009;123:789–794
  20. Wilcock LK, Francis JN, Durham SR. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am. 2006;26:333–339
  21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116–5121
  22. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008;121:343–347
  23. Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol. 1982;69:500–508
  24. MacGlashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol. 2004;114:1317–1324
  25. Clements JL, Yang B, Ross-Barta SE, Eliason SL, Hrstka RF, Williamson RA, et al. Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development. Science. 1998;281:416–419
  26. Yazdanbakhsh M, van den Biggelaar A, Maizels RM. Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol. 2001;22:372–377
  27. James JA, Sampson HA. Immunologic changes associated with the development of tolerance in children with cow milk allergy. J Pediatr. 1992;121:371–373
  28. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 2001;357:752–756
  29. Platts-Mills TA, Vaughan JW, Blumenthal K, Pollart SS, Sporik RB. Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response. Int Arch Allergy Immunol. 2001;124:126–129
  30. Francis JN. The facilitated antigen binding (FAB) assay—a protocol to measure allergen-specific inhibitory antibody activity. Methods Mol Med. 2008;138:255–261
  31. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120:688–695
  32. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252–3259
  33. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915–922
  34. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000;106:124–134
  35. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199:1679–1688
  36. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75–R81
  37. Liu Z, Yelverton RW, Kraft B, Tanner SB, Olsen NJ, Aune TM. Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. Clin Exp Allergy. 2005;35:1581–1590
  38. Guerra F, Carracedo J, Madueno JA, Sanchez-Guijo P, Ramirez R. Allergens induce apoptosis in lymphocytes from atopic patients. Hum Immunol. 1999;60:840–847
  39. Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R. TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol. 2001;107:647–653
  40. Tsai YG, Chien JW, Chen WL, Shieh JJ, Lin CY. Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy. Pediatr Allergy Immunol. 2005;16:602–608

 Supported by the Food Allergy and Anaphylaxis Network, the Gerber Foundation, National Institutes of Health grant 1R01-AI068074-01A1, the Arkansas Biosciences Institute, the Dorothy and Frank Robins Family, the Food Allergy Project, and Clinical and Translational Science Award 5M01-R000030-45.

 Disclosure of potential conflict of interest: A. W. Burks is a consultant for ActoGeniX NV, Intelliject, McNeil Nutritionals, and Novartis; is a minority stockholder of Allertein Therapeutics and MastCell Pharmaceuticals, Inc; is on the advisory board for The Dannon Company, Inc.; is on the expert panel for Nutricia; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Wallace Research Foundation; has served as an expert witness regarding food allergy; is on the Medical Board of Directors for the Food Allergy and Anaphylaxis Network; is on the Dermatological Allergy Committee for American College of Allergy, Asthma & Immunology; is a study section member of the National Institutes of Health Hypersensitivity, Autoimmunity, and Immunodeficiency; and is on the Journal of Allergy and Clinical Immunology review board. S. M. Jones is a consultant and board member for the Food Allergy and Anaphylaxis Network and has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, the National Peanut Board, Mead Johnson, and Dyax Corp. J. L. Roberts has received research support from the National Institutes of Health. A. M. Scurlock has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and Genocea Biosciences. T. T. Perry has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the Robert Wood Johnson Foundation, and Arkansas Biosciences Institute, Lyon. M. Kulis has received research support from the Food Allergy Initiative. W. G. Shreffler has received research support from the Food Allergy and Anaphylaxis Network. S. Durham has provided consultancy and lectures for and has received research support from GlaxoSmithKline and ALK-Abelló. B. P. Vickery has received research support from the National Institutes of Health and Ception Therapeutics. X. Zhong has received research support from the National Institutes of Health, the American Cancer Society, and the American Heart Association. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00813-6

doi: 10.1016/j.jaci.2009.05.022

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 2 , Pages 292-300.e97 , August 2009

Article Tools

* Image Usage & Resolution